Zuellig Pharma Strengthens Consumer Healthcare Portfolio with the Acquisition of Zam-Buk® and Vapex® Brands from Bayer

文章來源 : Media OutReach Limited 發表時間 : 2026/2/9 瀏覽次數 : 961 加入收藏 :

SINGAPORE - Media OutReach Newswire - 9 February 2026 - Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to the Zam-Buk^® and Vapex^® consumer healthcare brands from Bayer Consumer Care AG for Thailand, Singapore, Indonesia, Malaysia and Brunei.

Zam-Buk^® is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. First launched in 1902, Zam-Buk^® has retained strong brand equity over the decades and is widely perceived as a trusted household brand. Vapex^® is a nasal inhaler used to help relieve nasal congestion. Launched in 1917, Vapex^® has built meaningful brand recognition, particularly in Thailand.

The acquisition of the brands supports Zuellig Pharma's strategic priority to strengthen and scale its consumer healthcare portfolio across Asia. It also marks the company's second consumer healthcare acquisition, following Propan in the Philippines, reinforcing its focus on building a strong commercial platform for trusted, everyday healthcare products in the region.

"This acquisition marks another significant growth milestone for our consumer healthcare product portfolio. Zam-Buk^® and Vapex^® are enduring brands with deep heritage and trust in the communities they serve. By combining the brands' legacy with Zuellig Pharma's regional commercial capabilities and local market expertise, we aim to expand distribution and access across all relevant retail channels in the region. In doing so, these brands will continue to remain relevant, easy to find, and accessible to consumers." said John Graham, CEO of Zuellig Pharma.

Hashtag: #ZuelligPharma #ConsumerHealthcare #ConsumerHealth #Healthcare #Pharmaceuticals #Zambuk #Vapex #Bayer

The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

以上新聞投稿內容由 Media OutReach Limited 全權自負責任，若有涉及任何違反法令、違反本網站會員條款、有侵害第三人權益之虞，將一概由 Media OutReach Limited 承擔法律及損害賠償之責任，與台灣產經新聞網無關。

看看 Media OutReach Limited 的其他新聞

點此檢視本則新聞於 Google 的收錄

2026 年 8 月 19 日 (星期三) 農曆七月初七日